Information Provided By:
Fly News Breaks for January 8, 2020
TECH
Jan 8, 2020 | 09:06 EDT
Stephens analyst Jacob Johnson resumed coverage of Bio-Techne with an Overweight rating and $250 price target. The company's growth rate has accelerated in recent years from the low-single to the low-double digits and he see this continuing as Bio-Techne starts to benefit from its cell and gene therapy capabilities, Johnson said.